# A Perspective Study of the Antiviral Efficacy and Safety of Switching to TAF Treatment in CHB Adults With Suboptimal Response (SOR) and Intolerant to Entecavir

> **NCT04034368** · PHASE4 · UNKNOWN · sponsor: **The First Hospital of Jilin University** · enrollment: 8 (estimated)

## Conditions studied

- HBV

## Interventions

- **DRUG:** Tenofovir Alafenamide (TAF)

## Key facts

- **NCT ID:** NCT04034368
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08
- **Primary completion:** 2021-06
- **Final completion:** 2021-06
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2019-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04034368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04034368, "A Perspective Study of the Antiviral Efficacy and Safety of Switching to TAF Treatment in CHB Adults With Suboptimal Response (SOR) and Intolerant to Entecavir". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04034368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*